[1] |
GAROFOLI F, CIVARDI E, ZANETTE S, et al. Literature review and an italian hospital experience about post-ninfection acquired by breast-feeding in very low and/or extremely low birth weight infatal CMV ants[J]. Nutrients, 2021, 13(2):660.
DOI
URL
|
[2] |
LINDSAY J, YONG M K, GREENWOOD M, et al. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation[J]. Rev Med Virol, 2020, 30(4):e2108.
DOI
URL
|
[3] |
DING Y, RU Y, SONG T, et al. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-hodgkin lymphoma:the prevalence and impacts on outcomes:EBV and CMV reactivation post allo-HCT in NHL[J]. Ann Hematol, 2021, 100(11):2773-2785.
DOI
|
[4] |
JAKHARIA N, HOWARD D, RIEDEL D J. CMV infection in hematopoietic stem cell transplantation:prevention and treatment strategies[J]. Curr Treat Options Infect Dis, 2021, 13(3):123-140.
DOI
|
[5] |
MANUEL O, AVERY R K. Update on cytomegalovirus in transplant recipients:new agents,prophylaxis,and cell-mediated immunity[J]. Curr Opin Infect Dis, 2021, 34(4):307-313.
DOI
URL
|
[6] |
THOMAS E D, LOCHTE H L Jr, LU W C, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy[J]. N Engl J Med, 1957, 257(11):491-496.
DOI
URL
|
[7] |
BAZINET A, POPRADI G. A general practitioner's guide to hematopoietic stem-cell transplantation[J]. Curr Oncol, 2019, 26(3):187-191.
DOI
PMID
|
[8] |
YANG L, WANG Z, WU S, et al. The correlation between post-allo-HSCT CMV infection and the difference affinity of donor HLA-type recognition of CMV antigen peptide in children[J]. Zhonghua Xue Ye Xue Za Zhi, 2021, 42(9):757-762.
|
[9] |
KRAFT S, BOLLINGER N, BODENMANN B, et al. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease[J]. Bone Marrow Transplant, 2019, 54(4):540-548.
DOI
|
[10] |
GIMÉNEZ E, TORRES I, ALBERT E, et al. Cytomegalovirus(CMV)infection and risk of mortality in allogeneic hematopoietic stem cell transplantation(Allo-HSCT):a systematic review,meta-analysis,and meta-regression analysis[J]. Am J Transplant, 2019, 19(9):2479-2494.
DOI
URL
|
[11] |
LIU L, LIU Q, FENG S. Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation[J]. Ther Adv Hematol, 2020, 11:2040620720910964.
|
[12] |
VAVILOVA J D, BOYKO A A, PONOMAREVA N V, et al. Reduced immunosenescence of peripheral blood T cells in parkinson's disease with CMV infection background[J]. Int J Mol Sci, 2021, 22(23):13119.
DOI
URL
|
[13] |
HASSOUNEH F, GOLDECK D, PERA A, et al. Functional changes of T-cell subsets with age and CMV infection[J]. Int J Mol Sci, 2021, 22(18):9973.
DOI
URL
|
[14] |
HASSOUNEH F, LOPEZ-SEJAS N, CAMPOS C, et al. Effect of cytomegalovirus(CMV)and ageing on T-bet and eomes expression on T-cell subsets[J]. Int J Mol Sci, 2017, 18(7):1391.
DOI
URL
|
[15] |
LI S, SHEN Z H, WAN L P, et al. Cytomegalovirus pneumonia after allogeneic hematopoietic stem cell transplantation[J]. Zhonghua Nei Ke Za Zhi, 2021, 60(6):556-560.
|
[16] |
ZHANG P, YANG D, TIAN J, et al. A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation[J]. Ann Palliat Med, 2021, 10(5):5533-5540.
DOI
PMID
|
[17] |
GARCÍA-RÍOS E, NUÉVALOS M, MANCEBO F J, et al. Is it feasible to use CMV-specific T-cell adoptive transfer as treatment against infection in SOT recipients?[J]. Front Immunol, 2021, 12:657144.
DOI
URL
|
[18] |
SOMMERER C, SCHMITT A, HÜCKELHOVEN-KRAUSS A, et al. Peptide vaccination against cytomegalovirus induces specific T cell response in responses in CMV seronegative end-stage renal disease patients[J]. Vaccines(Basel), 2021, 9(2):133.
|
[19] |
KONDO E, AKATSUKA Y, KUZUSHIMA K, et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles[J]. Blood, 2004, 103(2):630-638.
DOI
PMID
|
[20] |
ENOK BONONG P R, BUTEAU C, DUVAL M, et al. Risk factors for post-transplant Epstein-Barr virus events in pediatric recipients of hematopoietic stem cell transplants[J]. Pediatr Transplant, 2021, 25(7):e14052.
DOI
URL
|
[21] |
LINDSAY J, OTHMAN J, YONG M K, et al. Dynamics of epstein-barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant[J]. Transpl Infect Dis, 2021, 23(5):e13719.
DOI
URL
|
[22] |
YOSHIMORI M, SHIBAYAMA H, IMADOME K I, et al. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection[J]. Blood Adv, 2021, 5(7):1805-1815.
DOI
PMID
|